SCHEMBL1481847

SCHEMBL1481847

C1CC[C](N2CCNCC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
HRH1 P35367 1/20 0.44
HTR2C P28335 3/20 0.40
HTR2A P28223 1/20 0.40
ADRB1 P08588 5/20 0.39
ALDH1A1 P00352 2/20 0.39
HTR3E A5X5Y0 2/20 0.39
HTR3B O95264 2/20 0.39
HTR3A P46098 2/20 0.39
HTR3D Q70Z44 2/20 0.39
HTR3C Q8WXA8 2/20 0.39
SIGMAR1 Q99720 2/20 0.39
CA2 P00918 1/20 0.39
CHKA P35790 1/20 0.39
LMNA P02545 1/20 0.39
CASP1 P29466 1/20 0.38
CASP4 P49662 1/20 0.38
CASP5 P51878 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28691107 1.00 USP2 (0.48) USP2SMN1; SMN2TDP1HRH1HTR2C
SCHEMBL1481868 0.92 ALDH1A1 (0.46) USP2SMN1; SMN2TDP1HRH1HTR2C
SCHEMBL28620324 0.86
SCHEMBL28013101 0.85 HRH1 (0.46) USP2SMN1; SMN2TDP1HRH1HTR2C
SCHEMBL368445 0.81 HTR2C (0.47) USP2SMN1; SMN2TDP1HRH1HTR2C
SCHEMBL11814285 0.80 USP2 (0.35) USP2ALDH1A1
SCHEMBL338532 0.78 HTR2C (0.49) USP2SMN1; SMN2TDP1HRH1HTR2C
SCHEMBL28615280 0.77 USP2 (0.44) USP2SMN1; SMN2TDP1ALDH1A1LMNA
SCHEMBL1824179 0.77 USP2 (0.44) USP2SMN1; SMN2TDP1ALDH1A1LMNA
SCHEMBL206437 0.77 USP2 (0.44) USP2SMN1; SMN2TDP1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023237049-A1 DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2023-12-14 WO disclosed
US-9637492-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2017-05-02 US disclosed
US-20150225407-A1 Benzothiazole Kinase Inhibitors and Methods of Use INTELLIKINE LLC 2015-08-13 US disclosed
US-8993580-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2015-03-31 US disclosed
US-8637542-B2 Kinase inhibitors and methods of use INTELLIKINE, INC. (US) 2014-01-28 US disclosed
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-05-26 US disclosed
US-20110077268-A1 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-03-31 US disclosed
US-20070082921-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077268-A1 KINASE INHIBITORS AND METHODS OF USE MAP3K20, MAP3K1, PDPK1 USP2 2475/4885SMN1; SMN2 4472/4885TDP1 1102/4885
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE MTOR, PDPK1, PIKFYVE USP2 3450/4885SMN1; SMN2 4783/4885TDP1 1243/4885
US-20070082921-A1 Quinazoline derivatives as antitumor agents ERBB2, EGFR, ERBB4 USP2 3550/4885SMN1; SMN2 4856/4885TDP1 2562/4885
US-20150225407-A1 Benzothiazole Kinase Inhibitors and Methods of Use MTOR, PDPK1, PIKFYVE USP2 3450/4885SMN1; SMN2 4783/4885TDP1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.